Mersana Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference

Rhea-AI Summary

Mersana Therapeutics, Inc. (NASDAQ:MRSN) announced its participation in the virtual panel at the 12th Annual Wedbush PacGrow Healthcare Conference on August 11, 2021, at 2:20 p.m. ET. The event will showcase the company's progress in developing antibody-drug conjugates (ADCs) targeting cancer. A live webcast will be available on their website, followed by an archived replay for 90 days. Mersana’s lead candidate, upifitamab rilsodotin (UpRi), is currently in trials for platinum-resistant ovarian cancer and NSCLC adenocarcinoma, alongside several other ADC programs.

CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the Company will participate in a virtual panel presentation at the 12^th Annual Wedbush PacGrow Healthcare Conference on Wednesday, August 11^th, 2021 at 2:20 p.m. ET.

A live webcast of the panel will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 90 days following the panel.

About Mersana Therapeutics

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration strategy in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1 umbrella study in combination with other ovarian cancer therapies. UpRi is also being evaluated in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.

Contact:

Investor & Media Contact
Sarah Carmody
617-844-8577
scarmody@mersana.com 

FAQ

When is Mersana Therapeutics participating in the Wedbush PacGrow Healthcare Conference?

Mersana Therapeutics will participate in the conference on August 11, 2021, at 2:20 p.m. ET.

Where can I watch the Mersana Therapeutics conference presentation?

The presentation will be available via live webcast on Mersana's website.

What is Mersana's lead product candidate?

Mersana's lead product candidate is upifitamab rilsodotin (UpRi), targeting NaPi2b.

In which clinical trials is Mersana's UpRi currently involved?

UpRi is involved in UPLIFT for platinum-resistant ovarian cancer and in studies for NSCLC adenocarcinoma.

How long will the archived replay of the Mersana presentation be available?

The archived replay will be available for approximately 90 days following the panel.